Universal API Implementation Guide - Local Development build (v1.1.20) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions

Release 2025 Jul 03

ANNOUNCEMENTS

• Susvimo indication for Diabetic Retinopathy (DR) was approved by the FDA on 4/28/2025.
• There is no change to Ophthalmology Prescriber Form version M-US-00006694(v6.0)
• FDA approved indications (ICD10 codes) can be found on the Access Solutions website for Susvimo
• Access Susvimo Copay questionnaires for updated indications.
  
  

Copay Enrollment - SUSVIMO

Type	Available in QA (test) environment?	Product(s) impacted	linkId impacted (if applicable)	OLD	New	Comment
Add	Yes	Susvimo	linkId: susvimo-fda-approved-indications	-	valueCoding.code: Diabetic-Retinopathy-(DR)-who-have-previously-responded-to-at-least-two-intravitreal-injections-of-a-VEGF-inhibitor valueCoding.display: Diabetic Retinopathy (DR) who have previously responded to at least two intravitreal injections of a VEGF inhibitor	New DR indication